Mechanistic Studies of Chronic COPD Using Single-Cell Sequencing and Single-Cell Spatial Transcriptomics
NCT ID: NCT07208123
Last Updated: 2025-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
150 participants
OBSERVATIONAL
2025-09-30
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population
NCT06724848
Heterogeneity and Development of Early COPD
NCT06096285
Lung Health of Early COPD: A Multi-center Cohort Study
NCT05466396
Multi-omics Studies of Host-microbiome Interaction in Chronic Obstructive Pulmonary Disease and Bronchiectasis
NCT05738044
A Study on COPD Phenotypes, Endotypes and Treatable Traits
NCT06952881
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COPD group
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with COPD according to the 2024 GOLD guidelines;
* Tissue samples that meet collection requirements and are either agreed to be collected or already preserved;
Exclusion Criteria
* Combined with other factors causing obstructive airflow limitation;
* Diagnosed with asthma according to the GINA 2023 guidelines and with a history of asthma exacerbations within the past year;
* Combined with Advanced lung cancer;
* Receiving systemic immunosuppressive medications such as anti-rejection drugs;
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tongji University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fang Chen
professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSCRNACOPD-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.